Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations

In conclusion, dabigatran etexilate may provide a viable and more convenient alternative to LMWH in the long-term treatment of VM-LIC. The dose has to be tailored in each patient in function of the bleeding tendency and laboratory hemostasis parameters.